# Radiolabeled Monoclonal Antibody, Paclitaxel, and Interferon Alfa in Treating Patients With Recurrent Ovarian Cancer

> **NCT00002734** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 30 (actual)

## Conditions studied

- Ovarian Cancer
- Primary Peritoneal Cavity Cancer

## Interventions

- **BIOLOGICAL:** recombinant interferon alfa
- **DRUG:** chemotherapy
- **DRUG:** paclitaxel
- **DRUG:** topotecan hydrochloride
- **RADIATION:** lutetium Lu 177 monoclonal antibody CC49
- **RADIATION:** yttrium Y 90 monoclonal antibody CC49

## Key facts

- **NCT ID:** NCT00002734
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1996-03
- **Primary completion:** 2001-04
- **Final completion:** —
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2013-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002734, "Radiolabeled Monoclonal Antibody, Paclitaxel, and Interferon Alfa in Treating Patients With Recurrent Ovarian Cancer". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT00002734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*